Liposomal drug delivery in cancer Miss. Kegade Prajakta*, Mr. Gade Akshay, Miss. Sawant Rutuja, Miss. Parkar Shreya Department of Pharmaceutics, M Pharmacy, University of Mumbai, Vidya Nagari, Kalina, Santacruz East, Mumbai, Maharashtra, 400098 *Corresponding Author E-mail: prajaktakegade95@gmail.com
Online published on 27 April, 2021. Abstract Nanomedicinal formulations are nanometer-sized carriers designed for increasing the drug tissue bioavailability, thereby improving the treatment of systemically applied chemotherapeutic drugs. Liposomes is one of the novel nanoscale drug delivery system which is a spherical vesicle with a membrane composed of phospholipid bilayer used for drug delivery. Liposomes have been considered to be most successful nano-carriers. Liposomes overcome the limitations of conventional chemotherapy by improving bioavailability and stability of drug also minimizing side effects by site specific targeted delivery, hence gain more advantages in cancer therapy. Cancer is a uncontrolled growth of cells. The cells causing cancer are called as malignant cells. Most of the active pharmaceutical ingredients used in the chemotherapy are highly cytotoxic to both cancer and normal cells to overcome this side effects liposomal treatment is useful. The liposomal drugs have high encapsulation capacity, hence shows a significant anticancer activity. The systemic administration of the free drug is considered to be the main clinical failure of chemotherapy in cancer treatment, as limited drug concentration reaches the tumour site. Most of the active pharmaceutical ingredients (APIs) used in chemotherapy are highly cytotoxic to both cancer and normal cells. Accordingly, targeting the tumour vasculatures is essential for tumour treatment. This short-review focuses on the use of liposomes in anti-cancer drug delivery. Top Keywords Liposomes, Anticancer, Nano-carrier drug delivery. Top |